This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SCML1 / Sex comb on midleg-like protein 1 · IHC design guide
Design Immunohistochemistry for SCML1
Plan SCML1 staining in paraffin sections around the distinct nuclear signal reported in seminiferous duct cells (HPA tissue IHC). This guide covers tissue controls, fixation consistency and interpretation of cytoplasmic positivity that was disregarded in the tissue profile (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SCML1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear in seminiferous duct cells (HPA tissue IHC) | |
| Staining pattern | Distinct nuclear staining in seminiferous duct cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A12084-1) | |
| Positive control | Duodenum+2 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent across samples and controls. (selected-SKU IHC image A12084-1) | |
| Caveat | Cytoplasmic positivity was observed but disregarded (HPA tissue IHC) | |
| Regulation | Broad fetal and adult expression (UniProt) | |
| Isoform / epitope | 3 isoforms; check epitope coverage across variants (UniProt) |
Section 1
Recommended SCML1 IHC & IF Protocols
The catalog antibody has an IHC-P protocol (datasheet A12084-1); one published SCML1 protocol uses frozen tissue sections (PMC2459175: methods).
| Sample | Paraffin-embedded human prostate cancer tissue; fixative not specified (datasheet A12084-1) |
| Fixation | Image fixative and duration unreported (datasheet A12084-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A12084-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A12084-1) |
| Primary antibody | Rabbit anti-SCML1, 2-5 μg/ml (datasheet A12084-1) |
| Primary incubation | Overnight at 4 °C (datasheet A12084-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A12084-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SCML1-positive staining in paneth cells of duodenum (HPA tissue IHC: High). HPA tissue profile: Distinct nuclear expression in cells in seminiferous ducts. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with heat-mediated EDTA retrieval at pH 8.0 (datasheet A12084-1). The published frozen-section protocol does not specify retrieval (PMC2459175: methods).
Section 2
What Is the Expected SCML1 Staining Pattern?
SCML1 should appear in nuclei, with distinct staining in cells of seminiferous ducts and high staining reported in pachytene spermatocytes and intestinal Paneth cells (UniProt Q9UN30; HPA tissue IHC). HPA rates tissue IHC reliability Enhanced, while reporting only medium consistency with RNA data and disregarding observed cytoplasmic positivity (HPA tissue IHC). SCML1 has no transmembrane segment (UniProt Q9UN30 topology).
| Distinct nuclear staining in pachytene spermatocytes or Paneth cells (HPA tissue IHC). | This matches the reported compartment and high-staining cell populations (HPA tissue IHC; UniProt Q9UN30). Score the relevant cells and their nuclei; tissue-wide staining alone does not establish the expected pattern (general IHC practice). |
| Predominantly cytoplasmic staining, with little nuclear signal. | Treat this as a suspect compartment pattern: HPA observed cytoplasmic positivity but disregarded it, while UniProt places SCML1 in the nucleus (HPA tissue IHC; UniProt Q9UN30). Review controls and staining conditions before calling cells positive (general IHC practice). |
| Strong staining in cells outside the reported positive populations (HPA tissue IHC). | Possible cross-reactivity or endogenous detection activity should be checked with appropriate controls (general IHC practice). HPA reports low tissue specificity at the RNA level, so an unexpected cell type cannot be rejected solely from the positive-cell list (HPA tissue IHC). |
| Diffuse staining across nuclei, cytoplasm, and surrounding tissue. | Poorly resolved compartment staining is difficult to interpret against the expected nuclear pattern (UniProt Q9UN30; HPA tissue IHC). Review blocking, washes, and detection controls for background; these are general IHC checks, not established SCML1-specific causes (general IHC practice). |
| No nuclear staining in pachytene spermatocytes or Paneth cells (HPA tissue IHC). | A known-positive cell population has failed to show its reported pattern (HPA tissue IHC). Check section quality, antigen retrieval, antibody dilution, and detection with controls before interpreting other sections as negative (general IHC practice). |
💡Expected SCML1 appearanceCall a positive result when staining is distinctly nuclear in pachytene spermatocytes or Paneth cells, populations reported as High; cytoplasmic-only staining is suspect because HPA disregarded cytoplasmic positivity (HPA tissue IHC; UniProt Q9UN30).
| Antibody validation | HPA rates IHC for HPA035270 and HPA035271 Enhanced; its tissue summary still notes medium staining–RNA consistency and disregarded cytoplasmic positivity (HPA antibodies; HPA tissue IHC). Interpret the observed compartment alongside controls (general IHC practice). |
| Isoforms | UniProt lists three SCML1 isoforms (UniProt Q9UN30). The supplied evidence gives no antibody epitope or isoform-specific staining data, so a different pattern cannot be assigned to an isoform from these sources (UniProt Q9UN30; HPA antibodies). |
| Processing and topology | UniProt annotates no signal peptide or propeptide, a 1–329 chain, and no transmembrane segment (UniProt Q9UN30). These annotations support a non-membrane interpretation but do not establish an epitope, retrieval condition, or fixation effect. |
| Modified residues | Phosphoserine is annotated at residues 138 and 238 (UniProt Q9UN30). No supplied source links either site to antibody recognition or IHC intensity; do not explain weak or variable staining as a phosphorylation effect from these data alone. |
| IF/ICC Q: Where should SCML1 appear? | A: Mainly in the nucleoplasm; HPA approves that subcellular location and lists ICC-IF images for A-431, U-251MG, U2OS, HEK293, and PC-3 (HPA subcellular). This localization answer does not specify an IF/ICC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| Testis section lacks the expected nuclear signal (HPA tissue IHC). | The section or staining run may have failed; the source does not identify an SCML1-specific fixation sensitivity. | Locate pachytene spermatocytes, then check section quality, retrieval, antibody dilution, and detection controls (HPA tissue IHC; general IHC practice). |
| Paneth cells stain weakly or inconsistently (HPA tissue IHC). | HPA reports High staining in Paneth cells, but its overall staining–RNA consistency is medium (HPA tissue IHC). | Confirm the cells in duodenum or small intestine and compare a known-positive control in the same run (HPA tissue IHC; general IHC practice). |
| Cytoplasmic staining dominates. | HPA observed cytoplasmic positivity and disregarded it; SCML1 is annotated as nuclear (HPA tissue IHC; UniProt Q9UN30). | Avoid scoring cytoplasm as the expected signal; inspect a reagent control and reassess detection background (general IHC practice). |
| Adipocytes or respiratory epithelial cells appear strongly positive. | HPA lists adipocytes in adipose tissue and respiratory epithelial cells in bronchus as Not detected; cross-reactivity or endogenous activity is possible (HPA tissue IHC; general IHC practice). | Confirm cell identity and compare a control without primary antibody before attributing that signal to SCML1 (general IHC practice). |
| Diffuse chromogen obscures nuclei. | Background can prevent compartment scoring; these data do not establish a target-specific cause (general IHC practice; UniProt Q9UN30). | Review blocking, washes, detection controls, and counterstain so nuclear boundaries can be assessed (general IHC practice). |
| An unexpected cell population stains in an otherwise usable section. | HPA reports low tissue specificity at the RNA level, so its listed IHC examples are not an exhaustive cell map (HPA tissue IHC). | Record the cell type and nuclear localization, then compare validated antibody staining and controls before making an SCML1 call (HPA antibodies; general IHC practice). |
Experiment evidence
IHC & IF images showing SCML1 staining
A12084-1 · IHCIHC analysis of SCML1 using anti-SCML1 antibody (A12084-1). SCML1 was detected in a paraffin-embedded section of human prostate cancer tissu
A12084-1 · IHCIHC analysis of SCML1 using anti-SCML1 antibody (A12084-1). SCML1 was detected in a paraffin-embedded section of human thyroid cancer tissue
A12084-1 · IFIF analysis of SCML1 using anti-SCML1 antibody (A12084-1) and anti-Tubulin Alpha antibody (M03989-3). SCML1 was detected in immunocytochemic
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000047634-SCML1/tissue/cerebral+cortex#imid_8569540
HPA · Adrenal glandHuman Protein Atlas IHC, Adrenal gland. Source: https://www.proteinatlas.org/ENSG00000047634-SCML1/tissue/adrenal+gland#imid_8569516
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000047634-SCML1/tissue/colon#imid_8569450
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000047634-SCML1/tissue/liver#imid_8569467
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA035270; green = SCML1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA035270; green = SCML1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SCML1 IHC & IF
🧪Run duodenum first: Paneth cells should stain (High; HPA: duodenum). Use adipose tissue as a negative comparator, where adipocytes are Not detected (HPA: adipose tissue); neighboring non-Paneth cells on the duodenum slide should provide a background reference, without assuming they are SCML1-negative.
Positive control tissue: Duodenum (Paneth cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SCML1 in A-431, U-251MG, U2OS, HEK293, PC-3, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), a matched rabbit IgG isotype control for the rabbit catalog antibody (caption: rabbit anti-SCML1), and SCML1-knockout material or a validated peptide-block control if available (standard IHC practice). Block endogenous peroxidase for DAB detection (caption: HRP/DAB), and check Paneth-cell granules for nonspecific staining (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A12084-1 paraffin-section caption does not state a fixative (caption: fixative unreported). That caption uses heat retrieval in EDTA pH 8.0, but does not establish whether retrieval is required; the supplied evidence also does not establish that frozen sections or IF are easier (caption: EDTA retrieval; HPA: ICC-IF images). Score the expected nuclear signal (UniProt: nucleus; HPA: approved nucleoplasm) separately from Paneth-cell granule staining (standard IHC practice).
HPA tissue IHC evidence for SCML1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Cytoplasmic positivity observed and disregarded.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Duodenum | Paneth cells | High | Protein (IHC) | HPA → |
| Small intestine | Paneth cells | High | Protein (IHC) | HPA → |
| Testis | Pachytene spermatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SCML1 IHC Tips
Troubleshoot SCML1 staining by checking nuclear localisation, cell type, section processing and background before interpreting chromogenic signal.
How should I optimise antigen retrieval when SCML1 nuclear staining is weak?
Begin with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A12084-1). Keep heating and cooling conditions consistent across test and control slides, and assess signal in pachytene spermatocytes or Paneth cells, where staining is high (HPA: high in pachytene spermatocytes and Paneth cells). The selected antibody’s paraffin-section example used 2 μg/ml primary antibody overnight at 4°C, so reproduce those conditions before changing retrieval (caption A12084-1). If nuclear signal remains weak, compare a more intensive retrieval condition on matched sections while watching for tissue damage and diffuse chromogen. Judge improvement by nuclear contrast, since SCML1 is nuclear and cytoplasmic positivity was disregarded in tissue assessment (UniProt Q9UN30: nucleus; HPA: cytoplasmic positivity disregarded).
Could fixation explain weak or uneven SCML1 staining in paraffin sections?
Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state a fixative (caption A12084-1: fixative not stated). Record each specimen’s fixative and fixation duration, then compare sections processed together so differences in antigen preservation can be assessed without changing several conditions at once. Start troubleshooting with the documented EDTA retrieval at pH 8.0 and the documented 2 μg/ml overnight primary incubation (datasheet A12084-1; caption A12084-1). Inspect morphology and nuclear staining together; damaged or unevenly processed regions can make a section difficult to score even when chromogen is visible. Do not infer SCML1 fixation sensitivity from its nuclear localisation, phosphorylation sites or tissue staining profile (UniProt Q9UN30: nucleus, phosphoserines 138 and 238; HPA: tissue IHC profile).
How should I investigate SCML1 staining outside nuclei?
Score nuclear staining first because SCML1 is annotated as nuclear, and its approved subcellular location is the nucleoplasm (UniProt Q9UN30: nucleus; HPA: approved nucleoplasm). Tissue assessment described distinct nuclear expression in seminiferous ducts and explicitly disregarded cytoplasmic positivity (HPA: tissue IHC profile). Compare cytoplasmic colour with a no-primary control and with regions showing expected nuclear staining; review counterstain alignment before assigning the colour to cells. Check whether diffuse colour follows folds, damaged edges or residual detection reagent, then repeat blocking and washing if needed. Report persistent cytoplasmic staining separately from nuclear SCML1 scores rather than treating both compartments as equivalent (HPA: cytoplasmic positivity disregarded).
Can isoforms or epitope accessibility explain discordant SCML1 IHC results?
SCML1 has 3 annotated isoforms, but the supplied antibody evidence does not map the catalog antibody’s epitope or establish which isoforms it detects (UniProt Q9UN30: isoforms 3, 1 and 2; caption A12084-1). Its SAM domain spans residues 258–325, and phosphoserines are annotated at 138 and 238; none identifies this antibody’s binding site (UniProt Q9UN30: domains and modified residues). First reproduce the documented EDTA pH 8.0 retrieval and 2 μg/ml overnight incubation on matched sections (datasheet A12084-1; caption A12084-1). If results still disagree, seek an independently mapped antibody or epitope information before attributing the difference to an isoform or modification. Compare nuclear localisation and the same cell populations across assays to keep the interpretation grounded in observed staining (UniProt Q9UN30: nucleus; HPA: tissue IHC profile).
How can I assess SCML1 by multiplex IF alongside chromogenic IHC?
Treat IF as a separate assay to optimise; the selected antibody evidence describes paraffin-section chromogenic detection with DAB, not an IF validation (caption A12084-1). Pair a nuclear SCML1 channel with a marker identifying the expected cell type, such as pachytene spermatocytes or Paneth cells, and assess nuclear overlap within those cells (HPA: high in pachytene spermatocytes and Paneth cells; UniProt Q9UN30: nucleus). Select fluorophores after viewing unstained tissue in each channel so tissue autofluorescence does not masquerade as a faint nuclear signal. Because SCML1 has no transmembrane segment and localises to the nucleoplasm, optimise permeabilisation for access to nuclear epitopes while preserving morphology (UniProt Q9UN30: topology and nucleus; HPA: approved nucleoplasm). Include single-channel and no-primary controls when assessing spectral bleed-through and background.
What should I check when SCML1 IHC shows diffuse brown background?
Run a no-primary control and inspect tissue edges, folds and damaged areas before changing the primary antibody concentration. The selected paraffin-section example used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, and a peroxidase-linked secondary for 30 minutes at 37°C (caption A12084-1). Confirm adequate peroxidase blocking and washing as general chromogenic IHC steps, particularly when DAB colour appears without a convincing nuclear pattern. Compare the background with nuclear staining in expected cell populations, and shorten detection or adjust primary concentration only after reviewing controls (HPA: high in pachytene spermatocytes and Paneth cells). Cytoplasmic positivity alone is weak evidence for SCML1 because it was disregarded in the tissue assessment (HPA: cytoplasmic positivity disregarded).
How should I quantify SCML1 staining across heterogeneous paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and score nuclear staining, since SCML1 is nuclear and cytoplasmic positivity was disregarded in tissue assessment (UniProt Q9UN30: nucleus; HPA: tissue IHC profile). Report the percentage of positive nuclei and intensity separately, or calculate an H-score from the proportions at each intensity; state the thresholds used. For spatial comparisons, report positive nuclei per mm² of viable tissue and normalise to the total nuclei or eligible cells in the same region. Analyse Paneth cells or pachytene spermatocytes as distinct populations where relevant, because both show high staining in the reference profile (HPA: high in Paneth cells and pachytene spermatocytes). Exclude folds, edges and necrotic areas using consistent rules, and keep retrieval, imaging and scoring settings fixed across samples.
When is SCML1 chromogenic staining convincing rather than artefactual?
A convincing result is cell-associated nuclear staining: SCML1 is annotated as nuclear, and tissue assessment reports distinct nuclear expression in seminiferous ducts (UniProt Q9UN30: nucleus; HPA: tissue IHC profile). High staining in pachytene spermatocytes or Paneth cells can support the pattern, while a negative cell population helps assess nonspecific colour (HPA: high in pachytene spermatocytes and Paneth cells; not detected in adipocytes). Review unexpected cytoplasmic colour cautiously because tissue assessment disregarded cytoplasmic positivity (HPA: cytoplasmic positivity disregarded). Exclude staining concentrated at section edges, folds or necrosis, and use a no-primary control to identify colour caused by detection reagents or endogenous enzyme activity. Interpret a positive result within the tested cell population and compartment, rather than assuming that ubiquitous RNA expression predicts uniform protein staining (UniProt Q9UN30: ubiquitous expression; HPA: low tissue RNA specificity and variable tissue IHC).
Boster reagents
Best SCML1 / Sex comb on midleg-like protein 1 IHC Antibodies
A12084-1 has IHC data from human paraffin-embedded cancer tissue and IF data from HeLa cells and human paraffin-embedded lung cancer tissue (A12084-1 image captions).
Real IHC data
Anti-SCML1 Antibody ®
Cat # A12084-1
A12084-1 is a human-reactive rabbit antibody listed for IHC, IF and ICC (catalog: A12084-1 applications, reactivity and host). Its IHC captions show human prostate, thyroid, liver and laryngeal cancer sections; its IF captions show HeLa cells and human lung squamous cell carcinoma sections (A12084-1 image captions).
Which to pick: Choose A12084-1 for human paraffin-section IHC; its own IHC captions document those samples and 2 μg/ml primary antibody (A12084-1 IHC captions). The same SKU supports IF/ICC selection, with captioned HeLa-cell IF and paraffin-section lung cancer IF at 5 μg/ml (A12084-1 IF captions; catalog: applications). No SKU here has documented cross-species reactivity; A12084-1 lists human only, while clonality and the tissue fixative are unreported (catalog: A12084-1 reactivity and clone; A12084-1 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UN30 (SCML1_HUMAN, Sex comb on midleg-like protein 1).
- Human Protein Atlas. SCML1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. SCML1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm..
- Human Protein Atlas. SCML1 antibody validation summary (3 antibodies).
- Adaptive evolution of SCML1 in primates, a gene involved in male reproduction. BMC evolutionary biology 2008 — PMC2459175.
- PubMed PMID:9570953 — UniProt-cited evidence.
- PubMed PMID:18601738 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SCML1 (Sex comb on midleg-like protein 1). Expected localisation Nuclear in seminiferous duct cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A12084-1). Validated IHC antibody: A12084-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Duodenum (Paneth cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human prostate cancer tissue; fixative not specified (datasheet A12084-1); 2. Fixation: Image fixative and duration unreported (datasheet A12084-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A12084-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A12084-1); 8. Primary antibody: Rabbit anti-SCML1, 2-5 μg/ml (datasheet A12084-1); 9. Primary incubation: Overnight at 4 °C (datasheet A12084-1). Watch for: Fixation: Keep paraffin-section fixation consistent across samples and controls. (selected-SKU IHC image A12084-1); Caveat: Cytoplasmic positivity was observed but disregarded (HPA tissue IHC); Isoform / epitope: 3 isoforms; check epitope coverage across variants (UniProt); Regulation: Broad fetal and adult expression (UniProt). Evidence: UniProt Q9UN30, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm., Datasheet A12084-1, PMC2459175. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SCML1/immunohistochemistry-ihc-guide.